Companies that own arGEN-X N.V.
Fidelity Management & Research Co.
3,245,060
10%
23,700
0.03%
08/29/2018
Federated Global Investment Management Corp.
2,891,897
8.91%
0
1.93%
12/31/2017
T. Rowe Price Associates, Inc.
1,680,077
5.18%
1,680,077
0.02%
05/14/2018
RTW Investments LP
1,436,705
4.43%
25,260
7.7%
12/31/2017
Perceptive Advisors LLC
1,124,478
3.47%
0
2.39%
12/31/2017
JPMorgan Asset Management (UK) Ltd.
802,852
2.47%
-163,140
0.06%
07/26/2017
Deerfield Management Company LP
576,816
1.78%
-11,764
1.54%
12/19/2017
OppenheimerFunds, Inc.
522,655
1.61%
-95,838
0.03%
02/28/2018
Bellevue Asset Management AG
396,819
1.22%
396,819
0.54%
03/31/2018
Norges Bank Investment Management
259,999
0.8%
3
0%
12/31/2017
| Address |
Willemstraat 5
Breda Noord-Brabant 4811 AH
Netherlands
|
|
Employees
|
- |
| Website |
http://www.argen-x.com |
| Updated |
07/08/2019 |
| argenx SE is a clinical-stage biotechnology company, which engages in the research and development of human monoclonal antibodies for the treatment of cancer and oncological, autoimmune, and inflammatory diseases. Its products include ARGX-113 for severe autoimmune diseases and ARGX-110 for T-cell lymphoma and acute myeloid leukemia. It operates through the following geographical segments: Netherlands, Belgium, Germany, Denmark, Switzerland, United States, and Luxemburg. |
